Showing results (71-80 of 102) with videos related to
Sort By:
Pageof 11
The Lancet. Rheumatology|January 31, 2024
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trialRoy Fleischmann, Alan Friedman, Edit Drescher, et al.Rheumatology and Therapy|November 24, 2021
Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid ArthritisPhilip Conaghan, Stanley Cohen, Gerd Burmester, et al.Lancet (London, England)|May 28, 2019
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 studyJosef S Smolen, Aileen L Pangan, Paul Emery, et al.Arthritis & Rheumatology (Hoboken, N.J.)|July 23, 2014
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritisStanley Cohen, Sebastião C Radominski, Juan J Gomez-Reino, et al.Journal of Pediatric Gastroenterology and Nutrition|June 30, 2009
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACHWallace Crandall, Jeffrey Hyams, Subra Kugathasan, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2011
Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitisJeffrey Hyams, Lakshmi Damaraju, Marion Blank, et al.Gastroenterology|February 28, 2007
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in childrenJeffrey Hyams, Wallace Crandall, Subra Kugathasan, et al.Current Medical Research and Opinion|January 19, 2011
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extensionJeffrey Hyams, Thomas D Walters, Wallace Crandall, et al.Arthritis and Rheumatism|October 19, 2011
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate aloneJoel M Kremer, Stanley Cohen, Bethanie E Wilkinson, et al.ACR Open Rheumatology|July 28, 2022
Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose StudyLubna Abuqayyas, Laurence E Cheng, Marcia Teixeira Dos Santos, et al.Pageof 11